PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Actinium Pharmaceuticals, Inc. (ATNM)
1.780.01 (-0.56%)
1.75 - 1.81
1.03 - 2.41
122.5K / 296.7K (Avg.)
-1.36 | -1.31
Shows the trajectory of a company's cash-generation capacity. Consistent growth in operating and free cash flow suggests a robust, self-funding business model—crucial for value investors seeking undervalued, cash-rich opportunities.
47.13%
Net income growth at 50-75% of AGEN's 67.53%. Martin Whitman would worry about lagging competitiveness unless expansions are planned.
3.87%
Some D&A expansion while AGEN is negative at -95.92%. John Neff would see competitor’s short-term profit advantage unless expansions here deliver big returns.
17.23%
Deferred tax of 17.23% while AGEN is zero at 0.00%. Bruce Berkowitz would see a partial difference that can matter for future cash flow if large in magnitude.
-49.98%
Both cut yoy SBC, with AGEN at -73.81%. Martin Whitman would view it as an industry shift to reduce stock-based pay or a sign of reduced expansions.
93.54%
Well above AGEN's 59.47% if positive yoy. Michael Burry would see a risk of bigger working capital demands vs. competitor, harming free cash flow.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
48.23%
Lower AP growth vs. AGEN's 131.74%, indicating prompt payments. David Dodd would confirm no lost opportunity in interest-free credit if expansions are underfunded.
21.18%
Some yoy usage while AGEN is negative at -28.08%. John Neff would see competitor possibly generating more free cash from minor accounts than we do.
-49.98%
Both negative yoy, with AGEN at -138.47%. Martin Whitman would suspect an overall environment of intangible cleanup or shifting revaluations for the niche.
33.57%
Some CFO growth while AGEN is negative at -39.95%. John Neff would note a short-term liquidity lead over the competitor.
-2609.70%
Both yoy lines negative, with AGEN at -7.91%. Martin Whitman would suspect a cyclical or broad capital spending slowdown in the niche.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-2609.70%
We reduce yoy invests while AGEN stands at 91.95%. Joel Greenblatt sees near-term liquidity advantage unless competitor’s expansions yield high returns.
5.36%
We repay more while AGEN is negative at -35899.97%. John Neff notes advantage in lowering leverage if competitor is ramping up debt or repaying less.
-80.40%
Both yoy lines negative, with AGEN at -100.02%. Martin Whitman suspects an environment or preference for internal financing over new equity in the niche.
No Data
No Data available this quarter, please select a different quarter.